

Gemtuzumab

Cat. No.:	HY-P99971
Target:	ADC Antibody
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Gemtuzumab is a monoclonal IgG4- κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia^[1] [2].

REFERENCES

- [1]. McGavin JK, et al. Gemtuzumab ozogamicin. *Drugs*. 2001;61(9):1317-22; discussion 1323-4.
- [2]. Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia. National Cancer Institute. 2017 Sept.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA